If you are a member of the general public and not a healthcare professional, NOVELTY study investigator or AstraZeneca Medical employee, please CLICK HERE to see information tailored to you.
The COVID-19 pandemic and NOVELTY: how do we turn the challenge into an opportunity to generate world class science?
The COVID-19 pandemic is a key transformative event in the lifetime of the NOVELTY study. The NOVELTY Scientific Community, along with the AstraZeneca study team, are coming together to address this challenge. However, the NOVELTY study also provides a unique opportunity to better understand the risk and outcomes of COVID-19 infection in patients with asthma and/or COPD. Today, as the AstraZeneca study lead, I would like to share with you some news about what is being planned regarding collecting additional data in NOVELTY, to answer some important questions about COVID-19.
The NOVELTY Scientific Community has identified several key research questions that we believe NOVELTY should address:
To answer these questions, we are considering several activities, including dedicated data collection, biomarker testing and sub-study initiation. Regarding data collection, we are progressing several avenues with the electronic case report form (eCRF) and patient-reported outcomes.
On behalf of the NOVELTY Scientific Community and study team, I would like to thank the study investigators and staff for their work on the study and for keeping track of COVID-19 data related to these patients. Together, we will contribute to managing this threat through rigorous data collection and evidence generation.
Hana Müllerová on behalf of the NOVELTY Scientific Community and the study team